completed his Ph.D studies in Organic Chemistry at Colorado State University, Colorado, USA in 1988, after which he joined Pfizer Pharmaceuticals as a Medicinal Chemist in Groton, Connecticut. Since joining Pfizer, he has worked in multiple therapeutic areas, including Cardiovascular, Metabolic Diseases, Osteoporosis, Frailty, Inflammation, and Immunology. He has made significant contributions to the discovery of multiple compounds that entered Human clinical trials, as well as working on early stage projects validating HTS hits, and progressing these molecules to chemical probes, and ultimately to clinical candidates. Currently, Dr. Lefker is a visiting scientist in the INCPM, and is working closely with Dr. Barr’s HTS group until he returns to Pfizer in the fall of 2017. Dr. Lefker is an author of 45 scientific publications and an inventor on over 60 patents and patent applications.
Khriesto A. Shurrush graduated Cum Laude from the University of Nebraska at Kearney in 2007 with a B.S degree in chemistry. He then continued his graduate studies under the guidance of Professor Arun K. Ghosh at Purdue University, were he developed synthetic strategies for the synthesis of aldol products by a non conventional aldol route and poly substituted furans. He also completed the total synthesis of tetrahydrolipstatin (Orlistat) used for the treatment of obesity and (+)-Neopeltolide a nano molar inhibitor of tumor cell proliferation.
Upon completion of his graduate studies in 2013 he returned to Israel to start his post-doctoral studies under the supervision of Professor Ilan Marek at the Technion-Israel Institute of Technology. Were he focused on the discovery of new chemical transformations using organo metallic reagents and there applications in enantioselective synthesis.
Nicolas Germain obtained a Bachelor in chemistry at the Université of Franche-Comté. He then moved to the University of Strasbourg (Master thesis supervisor: Prof. P. Pale) to complete a Ms.C. During his masters studies, Nicolas spent five months at the university of Osaka (internship supervisor: Prof. K. Mashima) and additional two months in the same lab before starting his doctoral studies at the University of Geneva (PhD advisor: Prof. A. Alexakis). At the University of Geneva, Nicolas’ work focused on Copper-Catalyzed Asymmetric Conjugate Additions of Grignard Reagents and Electrophilic Trappings of Mg-Enolates where he received his PhD in August of 2014. He then moved to Heidelberg for an industrial postdoc at CaRLa (Catalysis Research Laboratory, University of Heidelberg - BASF). In 2016 Nicolas joined the lab of Ilan Marek at the Israel Institute of Technology (Technion) as a Post Doctoral Student where he focused on new methodologies involving transition metals. His research interests range from organic chemistry to organometallic chemistry and main group chemistry. In July 2017, Nicolas joined the Medicinal Chemistry Team at the G-INCPM.